warfarin and clopidogrel

Pharmacodynamic interaction: Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X), reducing thrombin generation. Clopidogrel irreversibly inhibits the P2Y12 ADP receptor on platelets, blocking platelet activation and aggregation. The combined effect on haemostasis is additive, substantially impairing both the coagulation cascade and primary platelet plug formation.

Co-prescription significantly increases the risk of serious and potentially life-threatening bleeding, including gastrointestinal haemorrhage, intracranial haemorrhage, and bleeding at other sites. The risk is higher than with either drug alone and may be further increased by other factors such as age, concomitant NSAIDs, or chronic kidney disease.

Avoid concomitant use unless the benefit clearly outweighs the bleeding risk and no alternative exists. If combination therapy is considered essential, use the shortest possible duration, monitor INR frequently, and closely observe for signs of bleeding. Consider gastroprotection with a proton pump inhibitor (e.g., omeprazole or pantoprazole) in patients at risk of gastrointestinal bleeding. If invasive procedures or surgery are planned, the combination should be stopped appropriately in advance.

Well established. Clinical trials and meta-analyses consistently demonstrate increased bleeding risk when warfarin and clopidogrel are combined, including in patients with atrial fibrillation, coronary stents, or acute coronary syndromes. Current guidelines generally recommend avoiding this combination unless specifically indicated.